Albumin News and Research

RSS

Albumedix submits Drug Master Files for its products in Japan

Albumedix Ltd. (‘Albumedix’), the world leader in recombinant human albumin (rHA), announced today the submission of Drug Master Files (DMFs) to the Pharmaceutical and Medical Device Agency (PMDA) in Japan.

From Albumedix Ltd. 2 Feb 2021

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

From Albumedix Ltd. 2 Feb 2021

Urinary shedding of spike protein in COVID-19 patients

A team of scientists from the United States has recently revealed that about 25% of people with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop renal complications and that the viral spike protein can be detected in the urine samples of these patients. The study is currently available on the medRxiv* preprint server.

1 Feb 2021

Study uncovers new anti-inflammatory role for blood clot protein fibrinogen

Flinders University researchers have discovered a new anti-inflammatory role for well-known blood clot protein fibrinogen, which could support targeted new treatments for kidney, heart and other common diseases.

1 Feb 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

Researchers identify new biomarkers associated with incident heart failure

Researchers at the University of Eastern Finland and Kuopio University Hospital have discovered several new biomarkers that are associated with incident heart failure.

16 Dec 2020

Copper gluconate supplementation could reduce SARS-CoV-2 infection in vitro

The second wave of COVID-19 has affected many countries, costing thousands of lives and dealing further heavy blows to already reeling economies.

16 Dec 2020

Study: Structural racism has material impact on health of ethnic minorities, immigrants

Structural racism can lead to discrimination in many aspects of life including criminal justice, employment, housing, health care, political power, and education.

15 Dec 2020

Mild electrical stimulation with heat shock exerts protective effect against nephrotic syndrome

A research team from Kumamoto University in Japan has found that the combination of weak pulsed electrical current and heat exerts anti-inflammatory and anti-fibrotic effects in the kidneys, as well as a protective effect against nephrotic syndrome (NS) by inhibiting apoptosis (cell death) of kidney cells.

30 Nov 2020

Bioelectronic rapid test for COVID-19

A recent study presents a bioelectronic sensor platform to detect protein at the single-molecule level that is simple, rapid, and robust enough for widespread POC (point-of-care) or bedside application.

18 Nov 2020

Metabolic biomarkers could predict COVID-19 severity

A new study suggests that metabolic biomarkers could possibly predict the severity of COVID-19 in patients.

16 Nov 2020

Synthetic protein nanoparticle may treat aggressive brain cancer

A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

11 Nov 2020

Study shows dexamethasone can reduce chance of COVID-19-related death

Research has shown that dexamethasone, a widely available steroid, can significantly reduce the chance of death from COVID-19.

10 Nov 2020

High-impact clinical trial results could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25.

23 Oct 2020

Dexamethasone drug may not benefit COVID-19 patients with diabetes or low albumin levels

A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.

23 Oct 2020

Common kidney tests can help estimate risk of cardiovascular disease

Taking into account two common kidney disease tests may greatly enhance doctors' abilities to estimate patients' cardiovascular disease risks, enabling millions of patients to have better preventive cardiovascular care, according to a large international study co-led by researchers at the Johns Hopkins Bloomberg School of Public Health.

15 Oct 2020

New therapy may help treat or prevent multiple sclerosis

Multiple sclerosis, an autoimmune disease of the central nervous system that affects millions worldwide, can cause debilitating symptoms for those who suffer from it.

13 Oct 2020

Research indicates increased breast cancer mortality in African American and Black survivors

Although breast cancer does not discriminate between race or gender, research suggests that there is increased breast cancer mortality and poorer health-related quality of life in female African American and Black survivors of the disease.

6 Oct 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020